Vivet will be attending the 2nd Gene Patient Engagement congress with Sonia VALERO, Head of Clinical Operations and Patient Advocacy.
On the agenda, very interesting sessions and roundtables are planned, notably:
• Unique Characteristics of Gene Therapy & Their Ethical Implications For Clinical Trial Participation & Post-Approval Access
• Setting & Managing Expectations of Gene Therapy Within The Patient Community
• Building a Patient-Driven Informed Consent Process for a Gene Therapy
• Building a Patient-Centered Clinical Trial Protocol
On the agenda, very interesting sessions and roundtables are planned, notably:
• Unique Characteristics of Gene Therapy & Their Ethical Implications For Clinical Trial Participation & Post-Approval Access
• Setting & Managing Expectations of Gene Therapy Within The Patient Community
• Building a Patient-Driven Informed Consent Process for a Gene Therapy
• Building a Patient-Centered Clinical Trial Protocol
Vivet Therapeutics, a clinical-stage biotech company dedicated to developing gene therapy
Vivet Therapeutics BD Director, Thomas Daniel-Robin
Vivet Therapeutics CEO, Jean-Philippe Combal, will be participating to a panel during 2021 World Orphan Drug Congress Europe in Barcelona (Nov 15-18).
VIVET THERAPEUTICS ANNOUNCES 2 ORAL PRESENTATIONS AND 4 ABSTRACTS AT 2021 ESGCT ANNUAL MEETING
Vivet CDO, Anne Douar, will be presenting
Vivet Therapeutics Announces Multiple Projects Update, Including New VTX-803 Preclinical data To Be Presented At 2021 American Society Of Gene And Cell Therapy Annual Meeting
Jean-Philippe Combal, Vivet CEO, will be attending a panel during the Cell & Gene Meeting on the Med - virtual, organized by the ARM on April 6-9, 2021. The panel, "TRENDS AND CHALLENGES IN GENE THERAPY IN EUROPE", will be held on April 7, 3-4pm CET.
Jean-Philippe Combal, Vivet Therapeutics' CEO, and Thomas Daniel, BD Director, will be hosting 1x1 meetings during Jefferies 2020 London Healthcare Conference on November 17-19.